Details for Patent: 7,332,183
Which drugs does patent 7,332,183 protect, and when does it expire?
Patent 7,332,183 protects TREXIMET and is included in one NDA.
Protection for TREXIMET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixteen patent family members in fourteen countries.
Summary for Patent: 7,332,183
| Title: | Multilayer dosage forms containing NSAIDs and triptans | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independently and immediately. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | John R. Plachetka, Venkata Markandeya Kothapalli, Donna L. Gilbert | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Nuvo Pharmaceuticals (ireland) Designated Activity Co | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US10/741,592 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,332,183 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Drug Patent 7,332,183: Claim Scope, Treximet Patent Landscape, and Generic Entry RiskU.S. Patent No. 7,332,183 protects a specific physical architecture for combining naproxen or another NSAID with a triptan in one oral tablet. Its central limitation is not merely the combination of active ingredients. The patent requires substantially separate layers arranged side by side so that dissolution of the NSAID occurs independently from dissolution of the triptan. The patent was assigned to Pozen Inc. and relates directly to the formulation concept used for Treximet, the fixed-dose combination of sumatriptan succinate and naproxen sodium. The patent’s ordinary 20-year term ran from the relevant U.S. filing date and has expired, subject to any applicable patent-term adjustment or regulatory extension shown in USPTO and FDA records. The patent therefore presents historical formulation significance but does not, by itself, create a current barrier to generic entry. What does U.S. Patent 7,332,183 protect?The patent protects a multilayer pharmaceutical tablet containing two pharmacologically different components:
Claim 1 is the principal composition claim. It requires both chemical content and physical structure. A tablet containing sumatriptan and naproxen in a homogeneous blend does not satisfy the literal architecture of claim 1 because the actives are not substantially segregated into separate layers. Claim 19 broadens the NSAID component beyond naproxen. It refers to an “NSALD,” while the dissolution limitation refers to an “NSAID.” The apparent terminology inconsistency is likely intended to cover a nonsteroidal anti-inflammatory drug. The ambiguity could have affected claim construction in litigation, but the patent’s expiration now removes its practical enforcement significance. How do the independent claims differ?The patent has three principal independent claim groups. Claim 1: Multilayer tabletClaim 1 requires:
The independent-dissolution requirement is important. A two-layer tablet could still fall outside the claim if the layers are arranged or formulated so that the naproxen and triptan dissolve as a single interacting mass. Claim 13: Method of treating headacheClaim 13 covers administering a tablet within claims 1 through 8 at a dosage effective to alleviate headache pain. Claim 14 narrows the indication to migraine headache. These method claims depend on the underlying multilayer formulation. They do not independently protect the use of sumatriptan or naproxen in migraine treatment without the specified tablet structure. Claim 19: Multilayer tablet containing an NSAIDClaim 19 covers a tablet containing an NSALD or NSAID and a triptan, with the same separated-layer and independent-dissolution requirements. This claim may reach products containing NSAIDs other than naproxen, although the terminology defect and the specification’s disclosed embodiments would be relevant to claim construction. Claim 20: Rapid-release methodClaim 20 covers administration of the tablet of claim 4 or claim 5, with the requirement that dissolution of sumatriptan and naproxen is faster than dissolution from a tablet in which the ingredients are in physical admixture. This is a comparative performance claim. It creates evidentiary issues because infringement may require testing the accused product against a comparison formulation. The claim is narrower than a simple claim to a sumatriptan-naproxen combination. What formulations are protected by U.S. Patent 7,332,183?The patent protects several structural variations of the same multilayer concept.
Claims 6 and 7 describe a conventional bilayer tablet in which each active is concentrated on one side of a planar interface. Claim 8 extends the concept to a multilayer structure in which an intermediate layer separates the active-containing layers. The coating in claim 10 does not change the principal requirement that the active ingredients remain in separate layers. A conventional film coating surrounding the entire tablet can therefore fall within the claim if the internal architecture satisfies claim 1. What are the dosage and active-ingredient limitations?The most commercially relevant embodiment is:
Treximet is marketed as a fixed-dose combination containing 85 mg of sumatriptan base, supplied as sumatriptan succinate, and 500 mg of naproxen sodium. That dosage falls within claims 2, 4, and 5. The patent does not require a particular ratio between the two actives, tablet weight, excipient system, manufacturing equipment, coating composition, dissolution medium, or release specification, except where those characteristics are necessary to satisfy the independent-dissolution language. How does the patent distinguish a bilayer tablet from a physical admixture?The distinction is structural and functional. A physical-admixture tablet distributes sumatriptan and naproxen throughout a common blend before compression. The patented design places the components into separate tablet regions. The specification’s technical rationale is that the actives can have different dissolution characteristics and may interact adversely when mixed. A product is more likely to satisfy the claims when:
A product is less likely to satisfy the claims when:
“Substantially all” does not require absolute exclusion of the other active from each layer. Minor migration, residual carryover, or analytical detection below a material threshold may not defeat infringement. The precise threshold would depend on claim construction, the specification, prosecution history, and technical evidence. What is the FDA and Orange Book status of the patent?Treximet was approved by the FDA under NDA 021881. The product contains sumatriptan and naproxen sodium and is indicated for the acute treatment of migraine attacks with or without aura in adults (FDA, 2024). The FDA Orange Book historically listed U.S. Patent No. 7,332,183 for Treximet. Orange Book listing is relevant to ANDA certification and patent-notice procedures, but it does not extend a patent’s substantive term. Once the listed patent expires or is delisted, the patent no longer provides an active Orange Book barrier to approval.
The FDA’s regulatory exclusivity for the original product is separate from patent protection. New-drug exclusivity periods do not revive an expired formulation patent. When did U.S. Patent 7,332,183 expire?U.S. Patent 7,332,183 was granted on February 19, 2008. Its U.S. application was filed on October 31, 2003, and the patent’s ordinary 20-year term was therefore tied to the 2003 filing date, subject to patent-term adjustment and any applicable extension shown in official records (USPTO, 2008). The commonly cited expiration date for the patent is October 31, 2023. Patent-term adjustment, terminal disclaimers, continuation relationships, or a regulatory patent-term extension would need to be confirmed from the USPTO patent record and FDA Orange Book entry for the specific patent. Because the patent has reached the end of its ordinary term, claims 1-20 are no longer enforceable against commercial products solely on the basis of this patent. What Paragraph IV challenges affected Treximet?Generic applicants seeking approval before expiration of Orange Book-listed patents could file Paragraph IV certifications under the Hatch-Waxman Act. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed (21 U.S.C. § 355(j)(2)(A)(vii)(IV)). For Treximet, generic applicants faced several potential certification targets:
A Paragraph IV challenge to U.S. 7,332,183 would likely have focused on:
The 30-month stay available under Hatch-Waxman applies to timely patent litigation after notice of a Paragraph IV certification. It does not apply after the relevant patent has expired. Which companies challenged or competed against Treximet?The commercial competitive field included both branded and generic manufacturers.
Generic competition could avoid claim 1 by using a non-layered formulation, challenging the patent’s validity, waiting for expiration, or relying on a formulation that does not meet the independent-dissolution limitation. How strong was the patent estate for Treximet?U.S. 7,332,183 was technically meaningful but commercially narrow compared with a patent covering the active ingredients themselves. Strengths
Weaknesses
The estate’s practical protection depended more on the combined effect of several patents than on 7,332,183 alone. Later patents could have protected other aspects of Treximet, but they would require separate analysis of their claims, Orange Book status, prosecution history, and expiration dates. What generic launch scenarios existed?Three launch paths were commercially available. Design-around launchA generic manufacturer could formulate sumatriptan and naproxen in a single physical admixture or another structure outside the multilayer claims. The principal risk would shift to other patents and to regulatory requirements for pharmaceutical equivalence. Paragraph IV launchAn ANDA sponsor could challenge the patent before expiry and seek a commercial launch after the statutory stay period or following a favorable litigation outcome. The sponsor would need to address both the formulation patent and any later-listed patents. Post-expiration launchAfter expiration of U.S. 7,332,183, a generic could use a bilayer structure without infringing this patent, provided no other unexpired patent covered the product or its use. What manufacturing and intellectual-property barriers remain?The patent’s manufacturing concept requires controlled segregation of active ingredients during granulation, feeding, compression, and coating. Important manufacturing issues include:
Those manufacturing challenges are not, by themselves, enforceable patent rights after expiration. They can still create development cost, process-validation burdens, and quality-control requirements. How does U.S. 7,332,183 compare with a conventional fixed-dose migraine tablet?
Key Takeaways
Frequently Asked QuestionsDoes U.S. Patent 7,332,183 cover Treximet itself?Yes. The patent claims a formulation architecture consistent with Treximet, but it does not own the sumatriptan-naproxen active-ingredient combination in every dosage form. Can a single-layer sumatriptan-naproxen tablet infringe claim 1?Generally, not literally, because claim 1 requires separate first and second layers. Other patents, regulatory requirements, or equivalent-structure arguments could still be relevant. Does the patent cover naproxen without naproxen sodium?Claim 1 refers to naproxen broadly, while claim 2 specifically narrows the formulation to naproxen sodium at 200-600 mg. The scope depends on the particular claim asserted. Is independent dissolution required for infringement?Yes. The claim expressly requires dissolution of naproxen or the NSAID independently of dissolution of the triptan. Structural separation alone may not resolve every infringement issue. Can a generic manufacturer use the same bilayer design now?The expired patent no longer prevents that design by itself. A generic manufacturer must still evaluate any unexpired patents, regulatory requirements, trade secrets, and other intellectual-property rights affecting Treximet or its approved generic equivalent. References
More… ↓ |
Drugs Protected by US Patent 7,332,183
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926-002 | May 14, 2015 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Azurity | TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926-001 | Apr 15, 2008 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,332,183
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 546134 | ⤷ Start Trial | |||
| Australia | 2003303631 | ⤷ Start Trial | |||
| Canada | 2509023 | ⤷ Start Trial | |||
| Cyprus | 1112640 | ⤷ Start Trial | |||
| Denmark | 1575566 | ⤷ Start Trial | |||
| European Patent Office | 1575566 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
